argenx
ARGX · Nasdaq · Netherlands
Share price · ARGX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ARGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Oct 2026-11.8%
- 17 Aug 2026+16.0%
- 23 Jul 2026+8.6%
- 23 Jun 2026-5.6%
Nothing announced by ARGX that day or the session before.
- 5 Jun 2026+5.8%
Nothing announced by ARGX that day or the session before.
- 14 May 2026+2.4%
Nothing announced by ARGX that day or the session before.
- 11 May 2026+4.0%
Nothing announced by ARGX that day or the session before.
- 26 Feb 2026-5.6%
Nothing announced by ARGX that day or the session before.
- 27 Jan 2026+3.8%
Nothing announced by ARGX that day or the session before.
- 5 Jan 2026-4.7%
Nothing announced by ARGX that day or the session before.
Share of unusual movement by asset
For each asset, the share of ARGX's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Efgartigimod Alfa (Vyvgart)events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 39% |
| Sessions with no dated event | — | 61% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Efgartigimod Alfa(Vyvgart) | Approved | FcRnAntibody fragment | Myasthenia GravisChronic Inflammatory Demyelinating Polyneuropathy Generalized Myasthenia Gravis |
| Approved | FcRnAntibody fragment | Chronic Inflammatory Demyelinating PolyneuropathyMyasthenia Gravis Generalized Myasthenia Gravis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.